Schimelmitz IJ, Bross SD, Arrieta GJ, Guzmán URE, Jorba BS, Bravo EGA

Language: Spanish
References: 9
Page: 50-55
PDF size: 57.46 Kb.

ABSTRACT

The objective of this study was to determine the efficacy and safeness of the use of gatifloxacin at 400mg once a day in the treatment of acute bacterial sinusitis.
Design of the study: Open and no comparative, prospective, longitudinal.
We included the first 15 patients that came to the department of Otorhinolaryngology of the Hospital General Dr. Manuel Gea Gonzalez that were diagnosed with acute bacterial sinusitis. All the patients had computed tomography before and after treatment. Also we took pretreatment culture from the middle meatus.
The pretreatment cultures showed 4 patients without growth and other 4 with normal flora growing and the rest of the patients had Moraxella catharralis, Haemophilus influenzae and Corynebacterium spp between others.
The computed tomography had a 100% correlation with the clinical course and the return to the normality after the treatment.
The side effects observed were basically gastritis. All the patients in this study had a cured outcome with a good bacteriological response. Gatifloxacin at 400mg OD is a safe and secure medication for the treatment of acute bacterial sinusitis

REFERENCES

1. Gatifloxacina Investigator’s Brochure. Version number 3. Bristol-Myers Squibb Pharmaceutical Research Institute. October 1998.

2. Mayer H, Conetta B. Study AL 240-002. A Randomized, double blind multicenter, comparative phase III study of oral gatifloxacin versus clarithromycin in the treatment of community-acquired pneumonia requiring hospitalization. Final Study Report. Bristol- Myers Squibb Pharmaceutical Research Institute, 1998.

3. Mayer H, Conneta B. Study AL 420-037. A Randomized, double blind, multicenter, comparative phase III study of gatifloxacin versus ceftriaxone in the treatment of community-acquired pneumonia requiring hospitalization. Final study report. Bristol- Myers Squibb Pharmaceutical Research Institute, 1998.

4. Pierce P, Skuba K. Study AL 420-001. A randomized, double blind, multicenter, comparative study of gatifloxacin versus levofloxacin in the treatment of acute exacerbation of chronic bronchitis. Final study report. Bristol-Myers Squibb Pharmaceutical Research Institute, 1998.

5. Pierce P Skuba K. Study AL 420-020. A randomized, double blind, multicenter, comparative study of gatifloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis. Final study report. Bristol-Myers Squibb Pharmaceutical Research Institute, 1998.

6. Breen J, Macko A, Study AL 420-007, An open-label multicenter non-comparative phase II/III study of oral gatifloxacin in the treatment of acute, uncomplicated bacterial sinusitis inpatients undergoing sinus aspirate. Interim Study Report. Bristol-Myers Squibb Pharmaceutical Research Institute, 1998.

7. Nicaise C. IntegratedSummaryof Safety and Efficacy of gatifloxacin. Bristol-Myers Squibb Pharmaceutical Research Institute, 1998.

8. ChowAW,Hall CB, Klein JO et al. Evaluation of new anti-infective drugs for the treatment of respiratory infection. Clin Infect Dis 1992;15(suppl. 1):62-7.

9. Sinus and allergy health partnership. Antimicrobial treatment guidelines for acute bacterial rhinosinusitis. Supplement. Otolaryngology Head And Neck Surgery 2000:123(1)part 2